Reporter

Structural and molecular details of an anti-fungal target's interaction with inhibitors suggest ways to design better treatments for fungal infections.

Television viewers in Middle Tennessee will begin to see new messages from Vanderbilt University Medical Center this week that build upon the “Promise of Discovery” theme to describe the Medical Center's work and mission.

More than half of hospitalizations due to influenza pneumonia could be prevented by influenza vaccination, according to a study led by investigators at Vanderbilt University Medical Center, published this week in the Journal of the American Medical Association.

The glutamine transporter protein appears to contribute to the survival of lung cancer cells, suggesting it may be a useful diagnostic biomarker and target for therapies.

New findings add to the understanding of how the enzyme COX-2 works, which is critical to the development of COX-2-targeted anti-inflammatory drugs.

Vanderbilt University has received a contract from the Centers for Medicare and Medicaid Services (CMS) for up to $28 million over four years to help more than 4,000 clinicians in the Southeast transform their clinical practices in ways that improve quality of patient care and hold down costs.

La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders.